Press language:
early May 2023，Leaders of Shaanxi Pharmaceutical Group led a team to Guangzhou and Qingdao to participate in the 133rd Canton Fair and the 86th National Drug Fair。Visit learning，Cooperative negotiation，Extensive communication，Growing Observation，Breaking the vision，Deepen the understanding and thinking of the development of the pharmaceutical industry and the group。
The wind of Daxing investigation is the call of the Party Central Committee，It is an important content of theme education。现将Secretary of the Party Committee and Chairman of the Medical Research InstituteRen Jianping，Zhang Feng, general manager of biotechnology，Li Yinan, deputy minister of the capital and capital department, visited the survey report after the investigation as the first batch of research results of theme education to publish，For everyone to learn from。
Follow -up we will publish some high -quality survey reports。Hope the group system Daxing investigation and research，In -depth thinking to solve the problem of stagnation points that restrict the development of the group's development，Counseling to promote the high -quality development of the group。
Stake Sports Betting
stake online sports betting
Secretary of the Party Committee and Chairman of the Medical Research Institute Ren Jianping
Chinese medicine is the treasure of the Chinese nation，It has made an indelible contribution for the reproduction and health of the Chinese nation。In recent years，General Secretary Xi Jinping has made important instructions on the development of the Chinese medicine industry many times。The 20th report of the party also proposed，Promote the development of Chinese medicine inheritance and innovation。February 2023，The General Office of the State Council issued the "Implementation Plan for the Development of Traditional Chinese Medicine Promotion and Development"，Clarify the basic principles of promoting the development of traditional Chinese medicine，Eight key projects and 26 construction projects in overall planning。Overclocking the "Outline of Traditional Chinese Medicine Development Strategic Plan (2016-2030)", "Opinions on Promoting the Innovation of TCM inheritance and Innovation", "14th Five -Year Chinese Medicine Development Plan" and other major policies，The innovation and development of traditional Chinese medicine inheritance has risen to national strategy，We ushered in new historical development opportunities。Relying on the endowment of traditional Chinese medicine resources in our province，Combined with the investigation of the "Canton Fair" and the actual situation of the group，Make proposal for the development of the group's Chinese medicine sector，Unexpectedly，Please criticize and correct。
1. Fusion of the same chain for development
With a good industrial foundation，Group has accelerated the layout of the Chinese medicine industry in recent years，Established the planting of Chinese medicinal materials、Drinks processing，Patenting to Chinese medicine、Marketing and other traditional Chinese medicine chains，But there are also scattered weakness、Each is politics、Questions that have not merged development。For example，Group production enterprise and traditional Chinese medicine planting、There are fewer business relationships between beverage processing enterprises，There are more outsourced purchases of large medicinal materials; between ownership companies，In terms of market expansion and marketing，Lack of collaborative mechanisms，Unable to form a marketing joint force，It may even form internal competition and resource waste。So，Collaborative purchasing medicinal materials and materials，Integrated system production and marketing，Fusion resources，Let the scattered industrial chain truly integrated，is the foundation for the stronger and stronger of the group's Chinese medicine sector。
2. Inheritance of innovation and promoting development
1. Cultivation of large varieties
According to the industry development model，Cultivating large varieties is the only way for Chinese medicine companies to achieve high -speed development。Data display，Deadline2020，The major traditional Chinese medicine varieties selling over 100 million in the market have exceeded 500，Total sales of large Chinese medicine varieties have accounted for 50%of the market share of the Chinese medicine market。From the perspective of domestic drugs in China，Treatment of cardiovascular and cerebrovascular and respiratory drugs is most likely to produce major Chinese medicine varieties。For example，Plusal thrombosisImplementation6 billion years of sales revenue，Danhong injection solution achieves 4.5 billion yuanannual sales income, Fulfang Dan Di Pills Realizing Year3 billion yuan sales income，Lianhua Qing Plague Capsule (Granules) achieves 6 billion annual sales revenue。Different from the price reduction pressure of chemical medicine，China Pharmaceutical Collection Policy is relatively mild，Big variety profit space can be guaranteed。Carefully select potential varieties，Increase investment，Development includes material basis、A secondary development of the mechanism and evidence -based medical research，is the best path to cultivate large Chinese medicine varieties，Group should pay attention to and speed up investment in this area。
2. New drug research and development
Speed the listing process of new Chinese medicines in China,Applying 12 pieces of new Chinese medicine listing for new Chinese medicines in 2021，7 pieces of applications for the listing of new Chinese medicines in 2022。Since 2023，More and more enterprises have begun to increase the field of Chinese medicine research and development，There have been 7 new Chinese medicine new medicines submitted to the listing application，26 types of Chinese medicine new drug declaration clinical，far exceeding the same period of previous years。The "Cold Winter" of the new medicine of Chinese medicine has passed，Industry inflection point has arrived。It is recommended that the group focus on the following aspects:First, modify the effective monomer component structure in Chinese medicinal materials。Screening from Chinese medicinal materials with active single components，Not only the basis for modernization of traditional Chinese medicine，It is also an important source of new drug development。According to statistics，Current marketMore than 200 modern drugs are directly or indirectly derived from Chinese medicinal materials，For example, artemisinin、ephedrine、Natrilia, etc.。Synthesis through chemistry、Biological synthesis，Structural modification of a single component extracted from medicinal materials，Get a new small molecule compound，Makes its poisonous side effects lower，The efficacy is better，Pharmaceutical economics is better，As a result, it is approved for listing (this type is classified as chemical medicine)。But its R & D is more difficult，The cycle is longer。According to the status quo of the group，Strengthen cooperation with well -known experts in the field，Give full play to the advantages of production, research, research and research cooperation，The best way to achieve this type of results。A new drug DPF project of the Institute and the IDHP project that cooperate with Professor Zheng Xiaohui belongs to this category。The second is the new medicine。Improved new drugs are optimization products，safer it、More effective、Better in response，With obvious clinical advantages。Especially in the field of children's medication，Improved new drugs have been sought after by major enterprises，JFK Pharmaceuticals commissioned GMQR developed by the Institute of Pharmaceutical Research Institute to follow this path。Third is the classic famous side. Classic famous prescriptions have become one of the direct sources of new Chinese medicine new medicines,In 2021，3 of which are from the classic famous recipe，The "three parties" that play an important role in fighting the new crown pneumonia -clear lung detox particles、Huishu and defeat poison particles、Xuanling Luo Poison Granules。But the right to interpret the original meaning of the classic famous Fang Fang、The research on clinical indications studies the recognition of the national expert academicians，The review method is mainly expert opinion，Therefore, classic famous resources currently have clinical practical resources more concentrated in field experts、Academician's hands。Fourth is the clinical prescription, internal preparation。New Chinese medicine for clinical prescriptions and internal preparations，Occupy most of the new Chinese medicine new medicines in the past three years。2020，2 new drugs are derived from clinical prescriptions; 2021，8 new drugs are derived from the clinical prescription，1 comes from the internal preparation。Clinical Examination Recipes and Internal Preparations，Generally have many years of clinical experience，It is a summary of long -term clinical practice，Safety and effectiveness have been better verified。Develop new medicines on this basis，Can shorten the R & D cycle，Reduce R & D risk。
Three, with each other for the same development
The ability and advantage of scientific and technological resource integration of the Medical Research Institute should be used，Around the traditional Chinese medicine industry，Strengthen Xi'an Jiaotong University、Air Force Military Medical University、Northwest University、In -depth cooperation of universities such as Shaanxi University of Traditional Chinese Medicine，Focus on cardiovascular and cerebrovascular diseases、Diabetes Drugs，Through project cooperation、Project introduction and other methods，Forms a clear product research and development pipeline。Accelerate the establishment of a Chinese medicine common technology research and development platform、Innovation consortium，Juggi to carry out key core technology research，Improve industrial agglomeration and innovation ability，Help the development of the Chinese medicine sector in the group。
Four, fast development outside the industry
Policy of the second child、Population aging、The outbreak of the new crown epidemic，It has spawned the huge needs of large health products。Research and Development of Big Health Products Research and Development，With less investment、cycle short、Features of low risk。Once explored a suitable marketing model，can achieve a large revenue scale。The Group's development of the big health industry has natural advantages:First, pharmaceutical companies produce large health products，easier to get consumer recognition。From the perspective of consumer behavior,，The extension of consumer cognition is easier than the formation of consumer cognition。Compared with other companies，Consumers' hearts are easier to identify with the health function of pharmaceutical companies，Because in the minds of consumers，The efficacy of the products of pharmaceutical companies already exists。The dazzling achievements of pharmaceutical companies in the field of big health products also prove this。2022，Baiyunshan realizes operating income of 10.47 billion yuan with Wang Laoji tea as its core,，The gross profit margin is 43.5%; Yunnan Baiyao achieves operating income exceeded 6 billion yuan with a toothpaste category as the core of the business，Toothpaste market share 24.4%，Continue to keep the market share the first; Shiba 癀 cosmetics、Daily chemical industry realizes operating income of 634 million yuan，Net profit 9,8.3 million yuan。Second, Shaanxi has rich Chinese medicine resources，Easy to develop big health products. Chinese medicine resources are unique health resources in my country，It is also huge potential、Economic resources with high development value。Shaanxi is an important birthplace of Chinese medicine culture，VegetableThe reputation of "Qin Di has no leisure grass"。Ancestral Mai Qinling is known as "Natural Plant Gene Library"，contains2,730 more high -quality plant drug resources，Among them, 32 kinds of high -quality land medicinal materials，More than 400 kinds of medicinal materials。Natural resources and Chinese medicineThe advantage of "Treatment of Diseases"，provides a strong support for the development of large health products。Third, the pharmaceutical research institute has certain advantages in the research and development of large health products。At the same time, the brand of Shaanxi Pharmaceutical Group、Brand of Medical Research Institute、The brand of the Chinese Medicine Research Institute can empower the product in the competition of the disorderly large health market。
5. Sailing to go out to the sea for development
China is a country of Chinese medicine，But the share in the global botanical medicine market is not high。Data display，inIn the market value of $ 16 billion，Japan accounts for 80%、South Korea accounted for 15%，and China only accounts for 3%-5%，China urgently needs to change from the major country of traditional Chinese medicine to a strong country。The "Belt and Road" initiative has been proposed，The state uses Chinese medicine as an important part of stake betting appthe "Belt and Road" initiative。General Secretary Xi Jinping has repeatedly proposed to strengthen the international exchanges and cooperation of Chinese medicine on different occasions。"Promoting the high -quality integration of Chinese medicine into the" Belt and Road "development plan (2021-2025) "" Fourteen Five -Year Plan，Co -construction of the "Belt and Road" national cooperation to build 30 high -quality Chinese medicine overseas centers，Issuing 30 international standards for Chinese medicine，Create 10 Chinese Medicine Culture Overseas Communication Brand Project，Construction of 50 international medicine cooperation bases and a number of national Chinese medicine service export bases，Strengthen the construction of overseas registration service platform for Chinese medicine products，Group Chinese Medicine Foreign Medical Team，Encourage social forces to adopt a market -oriented method to explore the construction of Chinese and foreign friendly Chinese medicine hospitals。Internationalization of Chinese medicine will definitely become a trend。Fully excavate Shaanxi Dharma medicinal materials，Make full articles around the medicinal materials around the field，Sailing to the sea，Seeking development，It is inevitable for the long -term development of the group's Chinese medicine sector。At the same time，State of the Belt and Road Initiative、Especially for research and development cooperation with traditional countries with herbs，Help these countries to formulate the standards for improving herbal medicines，Optimize the improvement of production technology，to promote the spread of Chinese medicine culture，Leading Chinese medicine products to seize the international market。
General Secretary Xi Jinping pointed out，Chinese medicine science condenses the deep philosophical wisdom and the health concept and practice experience of the Chinese nation for thousands of years，It is the treasure of ancient Chinese science，It is also the key to opening the treasure house of Chinese civilization。We are in an age of a policy superimposed direction，Innovation and development of traditional Chinese medicine inheritance、Land、People and。Rongchain Qiang Chain，Vigorously develop the group of Chinese medicines in the group，Rongchain Qiang Chain，Just right!
Stable and far away Stable and far away
踔 踔 promotes the high -quality development of Shaanxi Pharmaceutical Group
General Manager of Biotechnology Zhang Feng
arrangement according to the theme education work of the group party committee，The ownership enterprises of the group system have carried out survey and research work，Take the 86th National Pharmaceutical Exchange of China as an opportunity，Combined with the development situation of the domestic pharmaceutical industry and the actual development of biotechnology，The future development direction of the biotechnology sector of the anchor group，Help the Group's high -quality development into research topics，Formation of this survey report。
1,China's pharmaceutical and health industry is in a rapidly vigorous development period，Big Health will become the national economic pillar industry。
According to the release of the Pharmaceutical Fair, the scale of the exhibition of this medicine meeting120,000 square meters，More than 2,000 major medical health companies participating in the exhibition，More than 100,000 professional audiences。The crowd of the medicine Jiaotong Club was turbulent、Rubbing shoulder，fully highlight the booming momentum of China's pharmaceutical industry。
According to statistics from the China Business Industry Research Institute,In 2022, the size of the Chinese pharmaceutical market reached 1658.6 billion yuan。With the continuous and stable development of the Chinese economy and the improvement of the per capita life expectancy，The arrival of aging society，People have greater demand for medicine health。More than 1.4 billion people with a huge population、over 300 million elderly people、500 million chronic patients，Forming a huge pharmaceutical market demand。With my country's economic development and the rapid improvement of residents' living standards，House of health awareness gradually enhances，The total amount of medical and health expenditures in my country has shown steadily in recent years，In 2021，increased by 14.8%year -on -year，The proportion of per capita consumption expenditure is 8.8%。It is expected to be in the next 5 years，The size of the Chinese pharmaceutical market will continue to grow with a compound annual growth rate of 9.6%，and reached RMB 2287.3 billion in 2025。
two,The prosperous pharmaceutical industry will inevitably lead to the more intense competition in pharmaceutical companies。
People of the Hills of the Medicine Fair，Products full of dazzling，The manufacturer is dizzy，Show the prosperity of the industry。The value law of the market economy rule informs us，The huge prosperous market will inevitably lead to capital、Large production factors such as talents poured in。Among the existing pharmaceutical manufacturers in my country，There are very few manufacturers with independent intellectual property types，Product homogeneity is quite serious。The same medicines have dozens of or even hundreds of pharmaceutical companies produced at the same time，This has led to the increasingly fierce competition between pharmaceutical companies。Competitive projects and scope of the domestic pharmaceutical industry have been competing from simple quantity to quality competition、From the competition from improving economic benefits to the competition of monopoly market share、From the competition of local enterprises to the entire pharmaceutical industry chain，The degree of competition has reached white thermalization。
Chemical drugs still dominate the Chinese pharmaceutical market，The proportion is high48.96%，Although at the end of 2020，2393 chemicals and agent production enterprises above designated size，Dan Yangzijiang Pharmaceutical、Fosun Medicine、Stone Medicine Group、Chinese biopharmaceutical、Qilu Pharmaceutical、Hengrui Pharmaceutical and other large pharmaceutical industries，With scale efficiency、Capital accumulation and research and development capabilities form a monopoly on the market。A large number of smaller pharmaceutical manufacturing companies in the industry，Limited by your own volume and capital scale，I have no R & D and innovative ability，Do not master the raw material market，Survival is very difficult，Not to mention development。Display according to the Flower Shun Fangcai website，As of December 30, 2022，A shares have a total of 147 chemical pharmaceutical companies，Among them, in terms of increase，In 2022, only 42 companies realized the rise，It means 70 % of companies are in a decline，and 61 have fallen by more than 20%; in terms of market value，Among 133 chemical pharmaceutical companies (remove 14 new shares listed in 2022)，Only 43 have 43 realized market value，The proportion is 32.33%。There are more than one -third of the entire chemical sector.。
Chinese medicine market,In 2022, my country's Chinese medicine market size reached 455.7 billion yuan，There are 2160 Chinese medicine production enterprises in the country。But homogeneous competition is even more intense，Statistics of similar traditional Chinese medicine varieties in the country: 826 Banlangen granules、671 pads of compound Dan Dan、Liuwei Dihuang Wan 586、Liuwei Dihuang Pill concentrated pill 62、503 beef detoxification tablets、Qi Ju Dihuang Wan 381、356 wearing lotus tablets、350 in Buzhong Yiqi Pill、331 vitamin C Yinqiao tablets (including western medicine ingredients)、Shiquan Da Buwan 324、311 of Guipi Pills。
January 22, 2021，The State Council promulgated the "Notice on Accelerating Several Policies and Measures on Accelerating Traditional Chinese Medicine Development"，Further refinement of promoting the development of the development of the Chinese medicine industry，Twenty measures through six aspects，It covers the review approval of Chinese medicine review、Research and innovation、Safety Studies、Quality Source Management、Quality control of the entire process of production、Supervision after listing、Protection of varieties, as well as the standard system of traditional Chinese medicine、Technical support system、Talent Team、Regulatory science、International cooperation and other content。The country will support the construction of the Chinese medicine industry on the one hand，Promoting the development of Chinese medicine; on the other hand, it will strengthen Chinese medicine，Especially the quality management of Chinese patent medicine。At this Qingdao Medicine Fair，Shen Yong, Deputy Secretary -General of the Chinese Medicine Association and the Deputy Secretary -General of the Medicine Branch, interpret the policy of Chinese medicine collection。Shen Yong Forecast: By 2025，Sino -patent medicine varieties with a large market prescription in the hospital，All may be included in the collection of collection。In the context of the comprehensive spread of Chinese medicine collection，Chinese patent medicine market may face a new round of reshuffle，A large number of proprietary Chinese medicine companies will eliminate the situation。With the continuous advancement of national drug collection，China's pharmaceutical industry will be reshuffled，The reduction of the price reduction of generic drugs to low gross profit will become the norm，Last enterprise business expansion is becoming more and more obvious，Many small and medium -sized enterprises lose cost advantages and are difficult to maintain the original business and face the situation，The industrial structure will face reshaping。Therefore, the group is chemistry，The development of the development plan of China Academy of Pharmaceutical Industry，Pharmaceutical variety selection，Considering future policies and markets，Fully consider the price cost pressure that the collection may bring，Avoid variety homogeneous market competition，Looking for innovative products，The way to develop its own advantages。
3,Traditional pharmaceutical business model and interest distribution method and policy orientation are not suitable、Poor continuous，It will be changed。
At present, China's pharmaceutical industry is generally adopted"Hanging Gold Sales"、"Rebate Rebate" for sale，20 buckles used (20 % of the sales price of the factory)，80%of the sales price is occupied by marketing costs in various links。Give a rebate in the field of pharmaceuticals、Monopoly control sales and other behaviors are already the industry，Both waste medical funds，It also aggravated the burden on the patient，Sometimes it will cause induced over -medical medical treatment，Damage people's health rights。
January 2019，The State issued the "Pilot Plan for centralized procurement and use of drugs for national organizations"，Carry out centralized band volume purchases，Control the drug price through the procurement policy，Reduce government medical insurance expenses，Reduce the economic burden of the people。The "collection" in domestic medical reform has been carried out for 5 years，Organize eight batches of national drug collection。According to the "Public Announcement of the results of centralized procurement of drugs in China" published by Shanghai Sunshine Pharmaceutical Procurement Network，The average price reduction of the selected drugs in the collection is 56%，Cumulative can save more than 100 billion yuan per year。Entering normalization with the purchase of band volume，The industrial structure of Chinese pharmaceutical companies in the future、Business mode、Marketing and profit distribution methods will be completely changed。
May 8, 2023，The National Health and Health Commission and other 14 departments jointly issued"2023 Corriding in the field of pharmaceutical purchasing and sales and medical services, the main points of work points of work"，Requirement and perfecting the style of governance，Key to rectify the problem of prominent corruption in the field of medicine。This governance made arrangements three years ago，In 2019, the Ministry of Finance and the National Medical Insurance Bureau implemented the quality inspection of accounting information for 77 pharmaceutical companies，The focus of inspection is the cost of pharmaceutical companies、The authenticity of cost and income。It can be said that the country's commercial bribery of the pharmaceutical industryMake it clearly，But due to the impact of the epidemic，Special rectification of the medical industry has not been fully carried out，This union14 departments to re -wind rectification，The determination and actions of anti -corruption in the pharmaceutical industry of the party and the government must clear the original source，For the existing pharmaceutical business mode、Marketing methods have a significant impact。
The traditional gold sales model is completely contrary to the direction of existing policy -driven，With the expansion of the scope of the governments, and the in -depth development of anti -corruption struggles in the field of pharmaceutical purchases and sales，A large number of production of homogenized drugs and relying on marketing pharmaceutical companies will not survive，Facing the elimination of the situation。
Fourth, policy -oriented, promoting development with reform, systemPlan、Make the trend、Increased efficiency，Enhance the competitiveness of Shaanxi Pharmaceutical Group。
Industrial structure of the pharmaceutical industry、Adjustment of business mode，It also created new development opportunities for the development of Shaanxi Pharmaceutical。Shaanxi as a leading pharmaceutical company in Shaanxi，Learning policy、Use policy、System planning、Rongchain Qiang Chain、Make the trend、stronger and bigger。First, the development of industrial planning and development is common with national policies，Together with the government，aiming for the advantage of state -owned enterprises，Demonstrate your strength，Differential projects with economic benefits，Precision Force、Different Army protrusions，Promoting the Group's structural adjustment and improvement of operating efficiency。The second is to fully implement"Three Essence Management"，Organize refinement、Refined management、Operating lean。According to the requirements of state -owned enterprise reform，Really implementing labor、Personnel、Allocation of three system reforms，Contract -oriented management of the person in charge of the owners at all levels，To achieve "Can you sit back, the contract is calculated;OK well, the indicator is calculated; the income is more and less, and the performance is calculated”。Form institutionalization、Independent company assessment management and employment mechanism，Endogenous motivation to stimulate the development of the enterprise。Third is to promote the integration of professional resources in the group，Chain chain supplement chain strong chain。HeadquartersEstablishing a coordinated section of various professional and business departments,All majors implement intensive operation, resource sharing,Advantagescomplementary，Fine needles of the main body of the legal person、Digging potential increase efficiency、Increased development。Give full play to the main channel function of Pai Ang Pharmaceutical in Shaanxi Medicine Distribution and Distribution Plates，Sales as a faucet，Drive the development of the relevant industries of the group;、Xi'an Zhengda、Three pharmaceutical companies in TianningMore than 180 valuable Chinese patent medicine production approval numbers (now the new application for registration of a Chinese medicine production approval number is very difficult)，The production capacity of the vacantness of the pharmaceutical pharmaceutical of Sun Siyi is organically linked with the high -quality medicinal material raw materials of the Holy Caotang of Sini Medicine，Construction Chain Development、Make effective benefits，Promote efficiency with chain、Make effective benefits。
Diligence、Good at thinking、Mino。There is a leader of the Party Committee of Shaanxi Pharmaceutical Group，The majority of cadres and employees work together，Li Jing Tu Guan、踔，Shaanxi Pharmaceuticals this pharmaceutical carrier will definitely take the wind to break the waves、Stable and far away、Before dreaming。
5、Adhere to the innovation -driven strategy，Chuangzhan Biomedical Circuit，It is the road to a high -quality breakthrough in Shaanxi Pharmaceutical。
General Secretary Xi Jinping pointed out:"Implementation of scientific and technological innovation -driven strategies is the full innovation of promoting scientific and technological innovation as the core，Adhere to demand orientation and industrial development direction，Establish the main position of enterprises in scientific and technological innovation "。Biomedical is an innovative industry，It is an important industry related to the national economy and people's livelihood，Is the most active world innovation today、The most rapid strategic emerging industry。In recent years，countries around the world have promoted biomedical technology and its industrialization into national strategy，By increasing the intensity of R & D investment、Implementing a series of technology plans、Constantly improving the relevant industrial system。The biomedical industry is also highly valued by my country's government and the key support of national industrial policies。In May 2021, the National Development and Reform Commission released the "Fourteenth Five -Year Plan" Biomedical Industry Development Plan，The Shaanxi Provincial Government has also listed biomedicine as the six new pillar industries created by the focus of biomedicine。
The biomedical industry is rapidly developing from high -tech industries with development potential to the development of high -tech pillar industries，Enter the rapid development period，Biopharmaceuticals are already in the core position。2021 my country BioMedicineThe market size reaches410 billion yuan，It is expected that its market size will reach 497.5 billion yuan in 2023，is the fastest growing industry。
Shaanxi Pharmaceutical Group is the vanguard of Shaanxi pharmaceutical industry，It should take on the role of developing the main force of biomedicine，Shaanxi Pharmaceutical Group Biological Products Co., Ltd. was formerly known as the Shaanxi Biological Products Research Institute，Founded in 1969，Mainly engaged in the production of biological products，is the earliest biomedical company in our province，It is also the only two people in the five provinces in Northwest China to use a vaccine manufacturer。We should show the advantage，Give full play to the brand of state -owned enterprises、State -owned enterprise credit，Keep in mind and follow the XiGeneral Secretary of Jinping"Technology is the first productive force、Talent is the first resource、Innovation is the first motivation "teachings，Focus on the main business、aiming technology、Sapture the track、Du Xing Fang、Strong State，Practicing the Provincial Party Committee and Provincial Government's High -quality Project Promoting Annual Activities with actual actions，Create Qin Chuangyuan Shaanxi Pharmaceutical Biological Products Project into a high -tech content、Core competitiveness、Continuous vitality project，The "zero breakthrough"，Promoting the development of the biomedical industry of Shaanxi Pharmaceutical Group into the "fast lane"，Fill the blank of Xi'an as the largest national central cities in the five northwest provinces in human vaccine biomedical industries，Promote the adjustment of the industrial structure of Shaanxi Pharmaceutical Group，Accelerate regional biomedicine and large health industry gathering，Maintenance of national biological safety。This time from the medicine, no one uses vaccine products to exhibit，The vaccine market is still the seller market; and in 2022, my country passed the WHO vaccine quality system evaluation，I awarded a pass to the export of Chinese vaccines abroad。With the country's Belt and RoadStrategyPromotion，African countries will be a huge market。Some time ago, Shaanxi Pharmaceutical Group organized a group to visit Nigeria，None of the countries with more than 200 million people have no biopharmaceutical companies，Serious medicine and less medicine。Therefore, the construction of Qin Chuangyuan Shaanxi Biological Products Project on the one hand must be carefully calculated、Save everywhere、Reduce cost; on the other hand, we must adhere to high standards，Not only in line with my country's GMP drug production quality specification，reached the WHO pre -certification standard，Become the benchmark and flag of our province's biopharmaceuticals，Getting good economic benefits，Create a good social value，Promote the high -quality development of Shaanxi Pharmaceutical Group。
Optimized resource structure Stimulate capital momentum
Deputy Minister of Funds and Capital Department Li Yinan
The 20th National Congress of the Party is a healthy medical and health guarantee system、Promoting the construction of a healthy China layout、Improve people's physical fitness and other aspects，Open the path for the development of the pharmaceutical industry in the new period、Planning blueprint、Planning blueprint。Previous ten years，Relying on high -quality companies such as Xi'an Yangsen，The Group has ushered in ten years of high -speed development。Current，The Group has stood at the crossroads of the new development of the new century，There is both opportunities for development，Facing unknown challenges。How to grasp the current strategic opportunity period of health China，Lay a solid foundation for the Group's development in the next ten years，It is a major topic that needs to be studied and thinking。May 9-10, 2023，I participated in Qingdao Medicine Meeting、Qingdao Santa Group Research Investigation and Study。Through studying the development model of excellent enterprises at the medicine agency，Visit on the spot to learn about the business mode of Qingdao Shengde Group，Optimize the resource structure of the group，Stimulate the Group's capital to generate some inspiration and thinking。
1,experience and practice of some outstanding companies
(1)China Resources Sanjiu mergers and acquisitions reorganization to improve the company's market value
1. Continue to improve mergers and acquisitions and reorganization
As an old listed state -owned enterprise，The expansion and acquisition of China Resources Sanjiu stake betting appis worth thinking about。China Resources Group obtained non -prescription drug resources through acquisition of Sanjiu Pharmaceutical，Entering the Prescription Pharmaceutical Market through the acquisition of Shuanghe Pharmaceuticals。In 2016, acquisition of Hong Kong Chain Pharmacy China Resources Hall; 2018 Holding Chinese Medicine African Pharmaceutical Drigita Jiang medicine industry，In 2022, the acquisition of Kunmao Group; in 2023, 113 million acquisition of the cubic pharmaceutical industry under the cubic pharmaceutical business of listed companies。It is precisely because of this series of non -stop mergers and acquisitions，can gradually realize the prescription medicine of China Resources Panjiu in the prescription、brand side of non -prescription medicine，Medicine production、Medical circulation (distribution、Retail) The absolute leading position of the chain end。
2. Strengthen the innovation of chain built -up chain
In the construction of the modern industrial chain of traditional Chinese medicine，China Resources Sanjiu will be closely integrated with the experience experience of local Chinese medicine enterprises with the management experience of world -class enterprises，Strong chain through brand construction，Focus on creating high -quality trademarks in Chinese medicine products;，Strive to improve the toughness of competition in traditional Chinese medicine technology;，Continuous optimization of the upgrade and transformation of the Chinese medicine industry。China Resources Pharmaceuticals not only acquires the expansion brand，More through the deep empowerment of the brand，Enhance the influence of the brand world，Leading the traditional Chinese medicine industry towards high -quality development，Help the great country to strengthen the doctor to walk towards the world。
3. Grasp the advantages of state -owned enterprise policy
Examples of China Resources Pharmaceutical's successful acquisition of blood products leading Boya creatures，Reflected the recognition of capital for state -owned enterprises，Can be under the competition conditions of similar enterprises，Preferentially picking China Resources for priority to get valuable blood brand licenses。To make full use of state -owned enterprise resources，Actively communicate with the government，Apply for preferential policies、Low -cost funds、High -quality resource allocation，Only in the fierce market competition can steadily stand for。
4. Adhere to the pursuit of green environmental protection
China Resources Sanjiu has a wholly -owned subsidiary who has won the title of a national green factory—— Anhui China Resources Golden toad Pharmaceutical Co., Ltd.。China Resources Sanjiu formulates "China Resources Three Nine EHS Principles"，Putting "High Realm and High Standards" as the guidance principle of the company's environmental governance。China Resources Three -nine actively promotes the use of new energy，Actively implement new technology of energy conservation and emission reduction，Construction of resource -saving and environmentally friendly enterprises。
in2022 In the investment environment of the general cold winter of the pharmaceutical industry，China Resources Sanjiu realizes operating income of 18.079 billion yuan，increased by 16.3%year -on -year; net profit was 2.497 billion yuan，increased by 18.98%year -on -year。Since December 2021，China Resources Sanjiu's stock price has increased by more than 140%。2020-2022，China Resources Pharmaceutical's annual sales of over 100 million yuan have quickly increased to 28，and for many years, it ranks first in the overall ranking of over -the -counter pharmaceutical manufacturers released by the China ONA Pharmaceutical Association。
(2)Luyan Medical Innovation Integration and Expansion of Business Connotation
As ofAt the end of 2022，A total of 33 medical business listed companies in A shares，Including 25 medical circulation listed companies and 8 offline pharmacy listed companies，Comparison of local pharmaceutical circulation leading enterprises with similar prosperity with Paiang Pharmaceutical，The growth path of Lu Yan Pharmaceutical, a leading company in Fujian Province, listed in 2016, stake betting appis worth thinking about。
Luyan Medicine2022 business income 19.463 billion yuan，In 2021。Luyan Pharmaceutical's core competitiveness by improving drug distribution，Promoting the operation improvement of the e -commerce 2B project in the province，Improve the function of Yunshang Platform。By strengthening and improving medical logistics and distribution of hard power，Then improve pharmaceutical service capabilities、Market access ability、Terminal marketing ability and academic construction ability，The company's transformation and upgrade from pharmaceutical distributors to pharmaceutical management comprehensive service providers。
(3)Medical recreation cultivation model Log in to the capital market
1. Medical care rehabilitation deepen industrial supporting collaboration
Most of the pension models in my country are currently"Combination of Living and Nourishing"，Qingdao is the first pilot in my country、Deep integration of the benchmark city of "combination of medical care"。Qingdao Shengde Medical Nursing Rehabilitation Group actively responds to the call of national policy，Take the lead to carry out the new type of pension mode of "combining medical care"。San De pioneered the combination of "medicine" and "nourishing"，From the 1.0 era of the 1.0 era of medical and nursing institutions，Enter the 2.0 era that focuses on providing medical care for the elderly disabled，Then extend to provide rich formats for the elderly in the staying in、All -in -one、Refined、Professional、Humanized Elderly Nursing Nursing Service 3.0 Age，Now it has become the leading medical brand in Qingdao area。
2. Integrate mergers and acquisitions to expand industry landscape
In the exchange with Santa Group, I mentioned the model of Samsung Medical Group's acquisition of Mingzhou Hospital。Samsung Medical GroupEntering the medical industry in 2015，2015-2021，The proportion of medical service business income increased from 12%to 20%。Samsung Medical Group subsidiaries use the capital operation platform，Through the medical industry fund，Actively expand the breadth of the industrial layout，More than 20 investment hospitals have participated in the investment hospital。At the same time, explore the chain expansion mode of "in vitro cultivation -profit point -acquisition -expansion"，Form the chain service brand that can be copied by a profitable model。Company in 2021、Two acquisitions in 2022 respectively、5 rehabilitation hospitals，Future "M & A+Self -Construction" parallel，The territory of the medical industry expands steadily。
3. Following social needs to expand capital operation
In the exchange, St. De Medical mentioned this yearSanbo Brain Hospital Management Group Co., Ltd., which was successfully listed in May。Relying on Beijing Sanbo，The company opened the group operation、2021、Development of homogeneous management，Create replication、Expansion profit model。January 2014，The company established the three blogs of Kunming，Become the first third -level neuros specialist hospital in Yunnan Province。In December 2014, Chongqing Changan Hospital and Chongqing Jiangling Hospital were restructured into Chongqing Sanbo Changan and Chongqing Sanbo Jiangling。2017，Sanbo Brain Department and Fenne Group invested in the establishment of Fujian Sanbo。2021，Establishing Henan Sanbo in Zhengzhou, Henan。After years of development and exploration，Sanbo Brain Department has developed into a "medical and research" integrated medical group，Relying on the technical strength of Beijing Sanbo, the flagship hospital、Talent delivery、Management and service experience，Through self -built、joint venture、Reform and other methods have successfully realized the expansion layout in multiple regions。May 5, 2023，Sanbo Brain has successfully listed on the GEM of the Shenzhen Stock Exchange，Become a successful case of the medical recreation group borrowing the capital market。
4. Grasp the core of service to establish industrial barriers
From the establishment of a nursing home that combines lives and nursing，To the transition to become a pension industry with a combination of medical care，and finally realize the operation of the capital market，"Help the doctor，，The industrial circulation system of capital blessing。The characteristics of San Dekang Yang Yang Group are the quality of service that continues to iterate and upgraded，The characteristic of Samsung Medical Group is to quickly complete the replicable business mode of connection integration，The characteristics of Sanbo brain are excessive technical strength and mode migration ability。The core of medical recreation is "people -oriented"，Service quality is the core competitiveness of the medical industry。St. De Group established its own training school，Ensure that the quality of the service personnel is qualified。Sanbo brain has core diagnosis and treatment technology，Ensure that patients from public hospitals get the best diagnosis and treatment。Samsung Medical Layout the Kangyang Nursing Institute in the country，It ensures the reliable connection of service quality。Only through the service to break the brand，Only to attract capital to build nests to attract phoenixes，Then use the amplification effect of capital，Really realize the efficient docking of industrial reorganization with the capital market。Investment of General Capital of Shareholders of Santa Group、Successful landing in the capital market is a successful example.。
two,The main problems existing in the resource structure of the group
(1) Global India's market value growth limit
As a group ownership listed company and the leading enterprise in the national pharmaceutical packaging industry，Global Printing has passedIn 2022, non -public issuance received 750 million yuan in equity financing，and use this non -public release，The same frequency resonance as industry development，Provide sufficient financial support for performance growth，Greed up incremental space for the company's development。But the current Global India still has the size of "beauty but small"，The market value of the market in the provincial -owned listed company is low，At present, there is still more limitations such as market value improvement space。
(2) Pa from Ang Pharmaceutical Fund Strict
The scale of Pai Ang Pharmaceutical、Technology and market status ranks in the front square in the national pharmaceutical circulation enterprise，It is also a leading enterprise in medical circulation in Shaanxi and even five northwest provinces。But due to the characteristics of the medical circulation industry，Excessive precipitation of funds，Pai Ang Pharmaceuticals must maintain funds by a lot of debt financing，Asset liability rates are high。At the same time, it is relatively narrow to send the pharmaceutical financing channel，The financing period is relatively short，Limited use of funds，Can't increase the effectiveness of the use of funds。
(3) The original ability of traditional Chinese medicine companies is not strong
2022 Chinese medicine industry faces cold winter。Chinese patent medicine production、The operating income of traditional Chinese medicine decoction pieces increased year -on -year increased by 5.6%、5.5%。profit decreased by 1.1%year -on -year、31.9%。The main reason is that the price of Chinese medicinal materials rises sharply，As a result, the cost of Chinese patent medicine production enterprises generally increases。Group Chinese Medicine Manufacturing Enterprises generally have small profit margins、Product types are small、A prominent problem with narrow marketing channels，Under the background of the shrinking profit space of the industry，The profitability of the group's Chinese medicine manufacturing sector is more limited。Unexpectedly need to integrate mergers and acquisitions to release production capacity，Improve the original ability level of traditional Chinese medicine manufacturing。
（4）Insufficient integration of biological vaccine resources
Qin Chuangyuan Shaanxi Pharmaceutical Biological Products (vaccine) project is the Group's response to 145th strategic plan，Implementing the eight pillar industries of Shaanxi—— specific measures in the biomedical industry。The total investment of the project is about 1 billion yuan，Fundamental funds are the guarantee project to achieve smooth production，Integrated socialized high -quality technology、Talent、Important conditions for management resources，At present, the group's biological vaccine industry needs to introduce more high -quality resources。
(5) Fund marketization is not enough
Group Shaanxi Pharmaceutical Investment Management Company's marketization progress is not enough，restricted the speed and efficiency of the Group's fund investment，It also restricts the improvement of the management level of the group's private equity fund。
(Six) Oriental Smart Fund Gaps Large
Oriental Smart Project fully responds to the requirements of the National 14th Five -Year Circular Economic Development Plan，After the project is completed, it will become the largest waste paper recycling cycle comprehensive utilization industrial base in the northwest of my country，It will greatly promote the recycling of recycled resources in the Northwest region，Accelerate the construction of green low -carbon circular development economic system，Reduced carbon emissions near every year5 million tons，Help the implementation of the "double carbon target" in Shaanxi。Oriental Smart Project has a large funding gap。
(7) The starting stage of medical health care is still in the starting stage
Group Industrial Company around"Medical、Kang、Keep、Protection "industry plan，Reserved Shanhai Dan Hospital、Qinhan Yiyu Park Severe Nursing Institute、骊 养 养 公、Airport Hospital、Qujiang Duyi Family Medical Recruitment Center and other 5 categories of medical care projects combined with nursing homes。But the current progress is relatively slow，Restricted the company's smooth production and achievement。
3,Thinking and Suggestion
(1) Taking Global India as a platform to expand the market value
1. M & A quality target
October 2020，The State Council issued the "Opinions on Further improving the quality of listed companies"，Give full play to the main channel of the M & A and reorganization of the capital market，Encourage listed companies to revitalize memory、Increased efficiency、Transformation and development; November last year，The Securities Regulatory Commission issued the "Promotion of Promoting the Three -year Action Plan for the quality of listed companies (2022-2025)" for proposal，Continue optimizing the capital market financing system，Improving the M & A Reorganization Supervision Mechanism，Be better to promote the industrial chain supply chain through integration。Cases of China Resources Sanjiu revealed us，Active merger and acquisition of upstream and downstream industries that are adapted with the company，Can help the company quickly occupy the market，Augmented asset scale。China Resources Sanjiu is the business landscape of continuous extension，Accumulate high -quality brand resources，Forms a unique brand moat。As more brands are widely accepted by consumers，China Resources Sanjiu can gradually become a market value of listed companies，Enhance the stock price of listed companies，Then achieve the results of the growth of shareholders' equity。Global Printing passed the acquisition of a high -quality project standard for mergers and acquisitions，Extension industrial chain，Expansion market value，Provide rich returns for shareholders。High -quality high -quality enterprises with complementary upstream industries through mergers and acquisitions with Global India，You can use efforts to make assets，Through the leverage effect of capital，Expansion Global India's market value space，Give full play to the main channel function of the capital market。
2. Grasp the market policy
SelfSince the implementation of comprehensive registration in 2023，The motherboard optimizes the relevant regulations for mergers and acquisitions, reorganization and re -financing。With the implementation of the full registration system，M & A reorganization will be more marketable、Convenience。Marketization means that more companies will be in the background where the stock market valuation is relatively low，Accelerated development through mergers and acquisitions reorganization; convenience means that the company can carry out mergers and acquisitions and reorganizations.、More efficient。Specifically，Under a comprehensive registration system，The motherboard is connected through the registered system with the GEM and the science and technology board，Clarified the reorganization review and registration process of small fast (no more than 300 million yuan)，Improve the standard and pricing mechanism of reorganization，The reserve price of listed companies for the purchase of assets has never been adjusted to 20 % off the market reference price，Further expand the game space of all parties in the transaction，Increase the flexibility of pricing。Mainboard listed company securities issuance conditions are streamlined and optimized，and GEM、The issuance conditions of securities of listed companies in science and technology board tend to be consistent，Simple procedures for small amounts (from the exchange from the exchange to the CSRC for no more than 10 working stake sports betting appdays) and the pilot registration system of targeted convertible bonds will be promoted to the motherboard market.。The introduction of these preferential policies，It can promote the process of Global India's process of small mergers and acquisitions and re -financing.，effectively improving the utilization efficiency of the global printing capital market。
3. Strengthen market value management
The Group is alreadyIn 2022, the market value management of global stamps was investigated，I wrote a research report on market value management work，Proposal of the Global India's market value management work。The Group focused on the work procedures for the increase of the repurchase of the repurchase of major shareholders in 2023，It is proposed to go through the group specification management，Suggestions to boost the efficiency of global Indian affairs at the right time。Global Indiaers can cooperate with state -owned capital operation companies，Actively contact strategic cooperation agencies to cover listed companies research，Establish an interconnection mechanism with the capital market，Expand the company's influence in the capital market，Promoting the management of investor relationship between the company，Strengthen the exchange between listed companies and the capital market，Effective transmission company value。
(2) Expand the financing path from Pai Ang Pharmaceutical
1. Grabbing policy opportunities to accelerate the promotion of Pai Ang Pharmaceutical Listing process
The first is streamlined registration procedures.After the registration system reform，The audit will be transferred from the CSRC to the exchange，A review from the exchange，And the Securities Regulatory Commission will mainly from national policy、Industry characteristics and other perspectives to check the enterprise，Added the Science and Technology Innovation Advisory Committee、Industry Consulting Expert Library and other expert consultants，Increase the professionalism of the audit agency，Maintain the consistency and stability of the review scale。At the same time，The China Securities Regulatory Commission will be mainly responsible for supervision and restraint、Supervision and inspection，Strengthen the responsibility consciousness of the issuer intermediary agency and audit agency，Promote improvementIPO quality.
The second is clearly positioned.After the implementation of the comprehensive registration system，Multi -level capital market system is clearer，Basically cover different types of different industries、Enterprises at different stages of growth，Each of the positioning of the plate has its own focus、Disposter Development、Complement market pattern。Motherboard protruding"Blue Chip" feature，Focus on supporting business models mature、Stable business performance、Large scale、High -quality enterprises with industry representative，Pulling the gap with other sectors in terms of listing conditions。Science and Technology Board Focus on the core goal of supporting and encouraging the listing of "hard technology" enterprises，Focus on serving "hard technology" to play the role of the "test field" of the capital market reform，Improve the tolerance of "hard technology" enterprises。GEM serves growth innovation and entrepreneurial enterprises，Focus on Sanchuang and Four New (Adapt to development more relying on innovation、Creation、Grand Trend of Creative，Main service growth innovation and entrepreneurs，Support traditional industries and new technologies、New Industry、New business、New mode deep integration)，Allows unable profitable enterprises to go public on the GEM。The Beijing Stock Exploration Explorer is more in line with the development laws and growth of innovative SMEs，Focus on "Specialty New"，Efforts to create a service innovative SME。
Third, the listing standards are clear.Mainboard Listing Standard，No longer requires a profit threshold，Instead of setting up net profit+income/cash flow、Market value+net profit+income+cash flow、Market value+net profit+income and other multiple standards。Interbank competition determination，It will also strictly prohibit interbank competition under the approval system，relaxes to the proportion of the owner's operating income or gross profit of the issuer's owner's owner's operating income or gross profit of more than 30 % except for competitors.，The rest will not be regarded as competition in the industry。Determination of the review standard、Estimated audit time、The transparency of the review process、Telled the length of the review (from the average time from the submitted materials to the registration, the average time has been shortened to nine months)、relaxation of profit requirements and peer competition standards，Important changes under these registration system，All are conducive to sending the opportunity of the registration system，Accelerate the listing process。
Fourth is the active listing of the enterprise.Provincial enterprises such as traffic control group、Sanqin Environmental Protection、Shaanxi nonsense and other companies are vigorously promoting the progress of listing，Many enterprises have completed the reconstruction of the joint -stock system、Interbank competition ratio drop、Land Real Estate Certificate Photo Application、Preparation for listing such as the optimization of legal person governance structure。It is recommended to launch Pai Ang Pharmaceutical Listing Work，Appropriate brokers with the experience of sponsors in the same industry through bidding，Planning Pharma Pharmaceutical Listing Plate and Path。Listing companies that visit local pharmaceutical circulation，Detailed understanding of relevant procedures and precautions for listing of local pharmaceutical circulation enterprises。By visiting other provinces to be a reserve listed company，Detailed understanding of the main points and experience that you need to pay attention to in the province，Listing companies that visit local pharmaceutical circulation。
2. Actively use direct melody tools to optimize Pai Aang pharmaceutical debt problems
The fundamental reason for the excessive liability rate of Pai Ang Pharmaceutical assets is the pressure of a lot of funds for precipitation，The main reason for the precipitation of funds is that the account receivable turnover rate is too low，You can adjust it by direct financing tools。Compared with equity financing，The average review time of bond financing of the Shenzhen Stock Exchange is only10 working days，The review process is open and transparent。Bond financing can be issued pure credit，Product period can be long or short，The use of funds for funding is autonomous and flexible，Financing amount is suitable for supplementary funds、Project investment、Repair loan、Add registered capital and other aspects。Pai Ang Pharmaceutical Optimized Financial Statement through permanent debt that can be included in the "other equity tools"，Accounts receivable ABS through the issuance，Active receivables，Control asset -liability ratio，Reduce the risk of recovery of accounts receivable。
(3) Made with traditional Chinese medicine manufacturing as the bond to improve the original ability level
Group can promote Shanhai Dan Pharmaceutical、Tianning Pharmaceutical、Xi'an Zhengda Pharmaceutical、Xi'an Haixin Pharmaceutical and other enterprises to relocate to Sun Siyi High -tech Pharmaceutical Park in Shaanxi，Focus on making Shaanxi Sun Siyi High -tech Pharmaceutical Park into a demonstration base in the largest Chinese medicine innovation and development of Chinese medicine in western my country。Accelerate the cultivation of large varieties，Focus on the manufacturing of Chinese medicine、Chinese medicine drinking tablets、The integration layout of the Chinese medicine large health industry，Looking for the high -quality target of pharmaceutical listed companies to carry out mergers and acquisitions and reorganization work，Help the group of Chinese medicine sectors through capital operation、Clusterization development。
(4) Take biological vaccine as an opportunity to absorb high -quality resources
The Group will take the biological vaccine project as an opportunity，Actively apply for discount special loans to financial institutions，Absorbing social high -quality biological preparation team"Bringing capital"，The first phase of the equity investment through strategic shareholders，Bring an advanced team、Technology and customer resources，In the future, it will continue to extend the biomedical industry chain，Reorganizes high -quality CRO company through mergers and acquisitions、Biological Preparation Company, etc.，jointly cultivated the biological vaccine with the group。At present, the biological vaccine project has introduced strategic investment shareholders to invest in capital，The Group will actively match low -interest loans for biological vaccine projects。The two products of this project entered the first phase of the clinic，Perform share restructuring according to listing conditions，Grabbing the opportunity of comprehensive registration and landing and science and technology board support to encourage the listing of "hard technology" enterprises，Finally went public through the science and technology board，Fully amplify the capital agglomeration effect of the group's biological vaccine industry sector，Write a strong stroke for listed companies in Shaanxi hard technology。
(5) Taking fund investment as a tool reserve potential project
At the end of July 2022，The General Office of the State Council is deployed to establish a coordination mechanism for promoting important investment important projects，Coordinated and promoted investment policies such as financial instruments to implement。The combination of project investment and financial instruments，It has become more and more focus on the country's attention。To improve the decision -making efficiency of the fund project of Shaanxi Pharmaceutical Investment Management Company，The Fund and Capital Department has formulated a list of authorization lists of Shaanxi Pharmaceutical Investment Management Company Fund Projects and Group Private Equity Fund Management Measures (draft)，After the full connection with the group's investment system is fully connected，Accelerate the marketization operation of the group fund project。Group can invest in funds as tools，With fund participation as a channel，Taking the fund layout as the opportunity，Actively extend the potential biomedical project and the group's existing resource pilot combination，Entry first，For the follow -up group through mergers and acquisitions and reorganization、Equity investment、Counseling listing and other resources integration and opening up the front array space。
(6) Promote environmental protection upgrade with green low carbon
Group should play the advantage of state -owned enterprises，Actively apply for discount special loans to financial institutions，At the same time when the Oriental Smart Project matures，It is an Oriental Smart Expansion financing channel through green bonds。In 2022, 515 green bonds issued in my country's domestic market，increased by 5.75%year -on -year，The scale reaches 872016 billion yuan，43.35%year -on -year; as of the end of 2022，Green bonds cumulative issuance of 2.63 trillion yuan，The size of the stock is 1.54 trillion yuan。Green debt will become more and more popular in the bond market。Oriental Wisdom's green low -carbon attribute，It can be well combined with green debt products。Group can be when the conditions are mature，Introducing green debt for Oriental Wisdom、Double carbon debt、Low -carbon debt、Carbon neutralized bonds and other bond varieties，Not only does it solve the problem of funds gap，It has also used the market -oriented constraint mechanism in the product to promote the steady transformation of the enterprise。
(7) Medical recreation as a path extension industrial chain
The main customer group of Santa Group is the elderly for the severe disability，This is also the focus of focusing on the group's health care sector。Group can purchase through the acquisition、Into high -quality three -level hospitals，Form a differentiated competition pattern through the introduction of a hospital specialized medical team。Kangyang Projects reserved by the Group，Create a small town of a medical and nursing community，Make sure the quality of medical care and care。When the construction of medical institutions and medical and support institutions in Xi'an region is in the beginning of the scale，You can pass"1+X+N" mode，M & A potential hospitals and Kangyang Community。After having a certain scale，Extension of strategic investment institutions to participate，The operation of the professional operation team，Improved through hardware、Talent support、Management optimization，Use medical care to guarantee medical care，Breeding medical care with medical care，Form a closed loop of the industrial chain，operation through the capital market，Create 10 billion or even 100 billion -level medical care listed companies。
Optimize the existing resource structure of the group，With the expansion of the expansion、Activation of going out、Internal integration，Realize the strong connection of the Group's existing resources and social high -quality resources。After reasonable optimization of the resource structure of the group，Daniel Group Capital Platform，Taking a nest to attract phoenix，Absorb high -quality stake online sports bettingsocial capital to settle in，Use multi -level equity、Credit rights、Asset securitization and other financing tools，Improve the Group's asset securitization rate，Deep excavation、Continuous expansion Group's capital potential momentum。Through capital agglomeration and leverage effect，Strengthen the concentration of the group's resources、Project integration、Industrial integration，Tightly connecting the real realization of high -quality resources and high -quality capital、Complement and win -win，Finally formed a two -wheel drive of high -quality resources and high -quality capital、The virtuous cycle pattern that goes hand in hand，Fully improves the level of resource integration and capital operation capabilities。